Literature DB >> 9036923

Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF.

C P Denton1, S Xu, C M Black, J D Pearson.   

Abstract

Fibroblasts cultured from lesional skin in scleroderma (systemic sclerosis) demonstrate an activated phenotype that may be important in pathogenesis. Endothelial cell-derived cytokines can modulate fibroblast properties, and endothelial cell changes occur early in scleroderma. Thus, endothelial cell and fibroblast dysfunction may be linked through the paracrine activity of soluble endothelial cell products. We have explored endothelial cell-fibroblast interactions in vitro by investigating the modulation of scleroderma and control fibroblast properties by endothelial cell-conditioned medium (EC-CM). EC-CM caused a concentration-dependent stimulation of fibroblast DNA and protein synthesis and upregulation of cell surface ICAM-1 expression. Scleroderma fibroblasts showed consistently greater responses than control cells. Medium conditioned by mechanically wounded endothelial cells had a greater effect than that from resting endothelial cells. Pre-incubation of EC-CM with anti-bFGF significantly reduced the promotion of fibroblast thymidine incorporation but did not affect endothelial cell-induced leucine incorporation. Conversely, anti-IL-1 antibodies abrogated EC-CM-induced leucine incorporation and ICAM-1 expression but did not diminish thymidine incorporation. Recombinant bFGF or IL-1 modulated fibroblast properties similarly. These data demonstrate that endothelial cell-derived IL-1 and bFGF modulate fibroblast properties independently and that lesional scleroderma strains are more responsive than control fibroblasts to endothelial cell-induced modulation, which supports the hypothesis that altered endothelial cell-fibroblast communication may be involved in the pathogenesis of scleroderma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036923     DOI: 10.1111/1523-1747.ep12286455

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis.

Authors:  Ufuk İlgen; Müçteba Enes Yayla; Nurşen Düzgün
Journal:  Clin Rheumatol       Date:  2016-11-22       Impact factor: 2.980

2.  Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation.

Authors:  Ann E Brannigan; R William G Watson; David Beddy; Hilary Hurley; John M Fitzpatrick; P Ronan O'Connell
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 3.  Novel therapeutic strategies in scleroderma.

Authors:  C P Denton; C M Black
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

4.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers.

Authors:  C P Denton; X Shi-Wen; A Sutton; D J Abraham; C M Black; J D Pearson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

5.  Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.

Authors:  Elena Raschi; Daniela Privitera; Caterina Bodio; Paola Adele Lonati; Maria Orietta Borghi; Francesca Ingegnoli; Pier Luigi Meroni; Cecilia Beatrice Chighizola
Journal:  Arthritis Res Ther       Date:  2020-11-09       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.